Algeta to present new clinical data from three phase II trials with Alpharadin at ECCO 15 - 34th ESMO Congress

Oslo, Norway, 17 September 2009 - Algeta ASA (OSE: ALGETA), the cancer therapeutics company, announces that new clinical data from three phase II clinical trials with Alpharadin comprising its phase II efficacy and safety program will be presented at the joint 15th Congress of the European CanCer Organisation (ECCO) and 34th Congress of the European Society for Medical Oncology (ESMO). The congress will take place in the Internationale Congress Centrum Berlin, Berlin, Germany from 20-24 September 2009.

Alpharadin is Algeta's lead cancer therapeutic and has recently been partnered with Bayer. It is the first in a new class of alpha-emitting pharmaceuticals ('alpha-pharmaceutical') and is based on radium-223. Alpharadin is in a global phase III clinical trial (ALSYMPCA) designed to confirm its efficacy and safety as a targeted treatment for bone metastases in men with hormone-refractory prostate cancer (HRPC). Alpharadin is administered as a simple injection and has a unique mode of action whereby it targets bone metastases specifically and exerts a highly localized effect on tumor cells while minimizing damage to normal surrounding tissues. In phase II studies previously reported, Alpharadin demonstrated strong evidence that it can prolong patient survival, improve quality of life and offer a benign safety profile.

Data from the three phase II trials being reported at ECCO are:

BC1-02 - Two-year follow-up data from a 64-patient efficacy and safety study evaluating survival and long-term toxicity in men with bone metastases resulting from HRPC following treatment with Alpharadin.

A poster (Abstract No. 7.018) will be presented by Prof. Oyvind Bruland (Norwegian Radium Hospital, Oslo, Norway). Date /Time: 22 September 2009, from 09:00 to 12:00 hrs Session: "Genitourinary malignancies - Prostate cancer" Location: Exhibition Hall 14.1 (Poster Board 215)

BC1-03 - Final results from a 100-patient study investigating the pain-relieving effects and dose-response relationship after a single dose of Alpharadin.

A poster (Abstract No. 7.011) will be presented by Prof. Sten Nilsson (Karolinska Hospital, Stockholm, Sweden). Date /Time: 22 September 2009, from 09:00 to 12:00 hrs Session: "Genitourinary malignancies - Prostate cancer" Location: Exhibition Hall 14.1 (Poster Board 208)

BC1-04 - Final results from a 122-patient efficacy and safety study designed to compare the prostate cancer specific antigen (PSA) response rate of three different repeat doses of Alpharadin.

An oral presentation (Abstract No 7.003) will be given by Dr. Chris Parker (Institute of Cancer Research and Royal Marsden Hospital, Sutton, UK), who is principal investigator of the ALSYMPCA phase III study. Date/time: 21 September 2009, 11.45-12.00 hrs Session: Proferred Paper Session: "Genitourinary malignancies - Prostate cancer" Location: Hall 3

###

For further information, please contact

For Algeta Andrew Kay, CEO Gillies O'Bryan-Tear, CMO Thomas Ramdahl, EVP & CTO

 

+47 2300 6742 / +47 4840 1360 (mob) +47 23 00 7824 / +44 7971 986 813 (mob) +47 23 00 7990 / +47 913 91 458 (mob) post@algeta.com

Citigate Dewe Rogerson Mark Swallow / Helena Galilee / David Dible

+44 (0) 207 638 9571 mark.swallow@citigatedr.co.uk

 

About Algeta Algeta ASA is a cancer therapeutics company built on world-leading, proprietary technology. Algeta is developing a new generation of targeted cancer therapeutics (alpha-pharmaceuticals) that harness the unique characteristics of alpha particle emitters and are potent, well-tolerated and convenient to use.

Algeta's lead alpha-pharmaceutical candidate, Alpharadin (based on radium-223), has blockbuster potential for treating bone metastases arising from multiple major cancer types, owing to its bone-targeting nature, potent efficacy (therapeutic and palliative) and benign, placebo-like safety profile. Development of Alpharadin is most advanced targeting bone metastases resulting from hormone-refractory prostate cancer (HRPC), and it entered an international phase III clinical trial (ALSYMPCA) in mid-2008 based on compelling clinical results from a comprehensive phase II program. This trial is currently open for recruitment.

In September 2009, Algeta entered into an global agreement with Bayer Healthcare AG for the development and commercialization of Alpharadin. As part of the agreement, Algeta retains an option to co-promote Alpharadin in the United States and to share profits from future sales.

Algeta is also developing other technologies for delivering alpha-pharmaceuticals. These include methods to enhance the potency of therapeutic antibodies and other tumor-targeting molecules by linking them to the alpha particle emitter thorium-227. The Company is headquartered in Oslo, Norway, and was founded in 1997. Algeta listed on the Oslo Stock Exchange in March 2007 (Ticker: ALGETA).

Alpharadin and Algeta are trademarks of Algeta ASA.

Forward-looking Statement This news release contains forward-looking statements and forecasts based on uncertainty, since they relate to events and depend on circumstances that will occur in the future and which, by their nature, will have an impact on results of operations and the financial condition of Algeta. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements. Theses factors include, among other things, risks associated with technological development, the risk that research & development will not yield new products that achieve commercial success, the impact of competition, the ability to close viable and profitable business deals, the risk of non-approval of patents not yet granted and difficulties of obtaining relevant governmental approvals for new products.

###

ECCO press release<http://hugin.info/134655/R/1341743/321002.pdf>

Posted: September 2009

View comments

Hide
(web2)